ADC Therapeutics (NYSE:ADCT) Share Price Breaks Below Fifty Day Moving Average – Here’s Why

ADC Therapeutics SA (NYSE:ADCT – Get Free Report)’s share price crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $1.39 and traded as low as $1.28. ADC Therapeutics shares last traded at $1.3450, with a volume of 1,072,670 shares.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of ADC Therapeutics in a report on Thursday, October 15th. Guggenheim reduced their target price on ADC Therapeutics to $5.00 and set a “buy” rating on the stock in a report on Monday, August 17th. Finally, Wall Street Zen upgraded ADC Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $5.00.

Get Our Latest Stock Report on ADC Therapeutics

ADC Therapeutics Stock Performance

The stock’s fifty day moving average is $1.39 and its 200-day moving average is $2.38.

ADC Therapeutics (NYSE:ADCT – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.05. The firm had revenue of $21.72 million during the quarter, compared to analyst estimates of $18.70 million. During the same quarter last year, the business posted ($0.30) earnings per share. Equities analysts forecast that ADC Therapeutics SA will post -0.80 EPS for the current year.

Institutional Trading of ADC Therapeutics

Several hedge funds have recently added to or reduced their stakes in ADCT. Nantahala Capital Management LLC grew its stake in ADC Therapeutics by 2.0% in the third quarter. Nantahala Capital Management LLC now owns 12,576,184 shares of the company’s stock valued at $15,343,000 after acquiring an additional 250,000 shares during the period. AIGH Capital Management LLC bought a new stake in shares of ADC Therapeutics in the third quarter worth about $5,276,000. Bank of America Corp DE increased its holdings in shares of ADC Therapeutics by 2.0% in the first quarter. Bank of America Corp DE now owns 1,325,017 shares of the company’s stock worth $4,969,000 after acquiring an additional 26,433 shares in the last quarter. Opaleye Management Inc. bought a new stake in shares of ADC Therapeutics in the second quarter worth about $749,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of ADC Therapeutics during the first quarter worth about $1,122,000. Institutional investors and hedge funds own 41.10% of the company’s stock.

About ADC Therapeutics

(Get Free Report)

ADC Therapeutics is a biotechnology company headquartered in Epalinges, Switzerland. It develops antibody-drug conjugates (ADCs), medicines designed to use antibodies to deliver cell-killing agents to cancer cells. Its research has focused on blood cancers and solid tumors. The company’s lead product, ZYNLONTA (loncastuximab tesirine-lpyl), is an ADC that targets CD19. In the United States, it is approved for adults with relapsed or refractory large B-cell lymphoma after they have received two or more prior systemic treatments.

Recommended Stories

Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.